A Clinicopathological Study of Young-onset Hepatocellular Carcinoma

Anticancer Res. 2021 Jun;41(6):2933-2944. doi: 10.21873/anticanres.15075.

Abstract

Background/aim: The aim of this study was to describe the clinicopathological features of hepatocellular carcinoma (HCC) diagnosed at 40 years of age or below.

Materials and methods: Expression of CK19, Glypican-3 and β-catenin was assessed in clinical samples by immunohistochemistry (IHC). IHC expression was correlated with clinicopathological parameters. Hotspot mutations in TP53 gene were analyzed by sequencing.

Results: Thirty-six cases were included with a male to female ratio of 3:1. Eighty percent of cases were associated with chronic hepatitis B infection. CK19 and GPC3 were expressed in 61% and 56% of cases, respectively. Only one case demonstrated β-catenin over-expression. TP53 hotspot mutation was identified in 4 cases. Number of tumor nodules, vascular invasion, and preoperative serum AFP level were associated with prognosis.

Conclusion: A higher CK19 expression rate was observed in our young-onset HCC cohort, whereas β-catenin pathway activation and TP53 gene mutation events were less frequent. Conventional clinicopathological parameters remain predictors of survival.

Keywords: Liver cancer; immuno - histochemistry; mutation; young-onset.

MeSH terms

  • Adolescent
  • Adult
  • Age of Onset
  • Carcinoma, Hepatocellular / genetics
  • Carcinoma, Hepatocellular / metabolism
  • Carcinoma, Hepatocellular / pathology*
  • Child
  • Female
  • Genes, p53
  • Glypicans / metabolism
  • Humans
  • Keratin-19 / metabolism
  • Liver Neoplasms / genetics
  • Liver Neoplasms / metabolism
  • Liver Neoplasms / pathology*
  • Male
  • Mutation
  • Retrospective Studies
  • Young Adult
  • beta Catenin / genetics
  • beta Catenin / metabolism

Substances

  • CTNNB1 protein, human
  • GPC3 protein, human
  • Glypicans
  • Keratin-19
  • beta Catenin